Tradestie Institutional Equity Comparison Engine

LGND vs ELVN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LGND Overall Edge

LGND Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ligand Pharmaceuticals Inc. (LGND) driven by superior Valuation, Growth & Margin, Momentum & Technical while ELVN counters with relative strength in Options & Structure. Fundamentally, LGND trades at 25.8x Forward P/E with 14.4% operating margin (-31.8% YoY revenue) versus ELVN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LGND sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro) against ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LGND
LGND 25.8x vs ELVN N/M Fwd P/E
Growth & Margin Winner LGND
Op Margin 14.4% vs 0.0% ยท YoY -31.8% vs +0.0%
Momentum & Technical Winner LGND
1Y +51.5% vs +134.5% ยท 52W Pos 86% vs 69%
Options & Structure Winner ELVN
CONSOLIDATION (8th %ile IV) vs CONSOLIDATION (5th %ile IV)
LGND NASDAQ
Ligand Pharmaceuticals Inc.
Pharmaceutical Preparations
$304.93
-1.25% 1D
Market Cap $6.3B
1M Return +3.18%
1Y Return +51.5%
Forward P/E 25.8x
Unified AI Score
42.6 / 100 HOLD
Tech 44.0 Fund 47.0 Flow 63.0 Mom 31.1
ELVN NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
1M Return +27.38%
1Y Return +134.53%
Forward P/E N/M
Unified AI Score
36.2 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LGND +51.5% ELVN +134.53% Spread: +83.03 pp (ELVN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LGND TTM Op. Margin: 14.4% ELVN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LGND vs ELVN. Trailing 12-month operating profitability (LGND 14.4% vs ELVN 0.0%) and valuation multiples (LGND 25.8x vs ELVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LGND (9) vs ELVN (1)
Institutional Metric LGND ELVN Criterion Row Winner
Market Capitalization Scale $6.3B $3.6B Larger Scale LGND
Trailing P/E Ratio Valuation 127.0x N/M Lower Multiple LGND
Forward P/E Ratio Valuation 25.8x N/M Lower Multiple LGND
Revenue Growth (YoY) Growth -31.8% +0.0% Higher Growth ELVN
Operating Margin (TTM) Profitability 14.4% 0.0% Higher Margin LGND
Net Profit Margin Profitability 20.3% 0.0% Higher Margin LGND
Return on Equity (ROE) Capital Efficiency 5.4% -16.8% Higher ROE LGND
52-Week Range Position Momentum 86% ($176โ€“$327) 69% ($15โ€“$62) Stronger Trend LGND
Beta / 30D Volatility Risk Regime 0.99ฮฒ ยท 38% Vol 0.96ฮฒ ยท 60% Vol Lower Realized Risk LGND
Unified Institutional Score Composite Signal 42.6 / 100 (HOLD) 36.2 / 100 (SELL) Higher Composite LGND

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LGND vs ELVN Buy Guide
LGND CONSOLIDATION
98d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live LGND Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ELVN CONSOLIDATION
59d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live ELVN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LGND nor ELVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.